VPS35 Retromer Stabilizer for Lysosomal Rescue

VPS35 Retromer Pharmacological Chaperone

Overview

This therapeutic strategy targets the retromer complex — a master regulator of endosomal protein sorting — through pharmacological chaperones that stabilize the VPS35-VPS26-VPS29 trimer. The VPS35 D620N mutation causes autosomal dominant Parkinson's disease, and retromer dysfunction is now recognized as a convergence point linking APP mis-sorting in Alzheimer's disease, GCase trafficking defects in GBA1-linked PD, and lysosomal failure across multiple proteinopathies. Small-molecule retromer stabilizers (the R33/R55 class) have demonstrated preclinical efficacy in reducing Aβ production and rescuing lysosomal function, making this one of the most mechanistically compelling multi-disease targets in neurodegeneration.[@vilariogell2011][@small2005]

Target

• Primary Target: VPS35-VPS29 interface of the retromer cargo-selective complex
• Target Type: Pharmacological chaperone / protein-protein interaction stabilizer
• Expression: Ubiquitous; critical in neurons due to extreme endosomal trafficking demand (synaptic vesicle recycling, receptor sorting)
• Localization: Endosomal membrane; cycles between early endosomes, recycling endosomes, and trans-Golgi network

Mechanistic Rationale

The retromer complex sorts cargo proteins from endosomes back to the trans-Golgi network (TGN) or plasma membrane. Its dysfunction causes catastrophic cargo mis-sorting, with downstream consequences across multiple neurodegenerative disease pathways:[@vilariogell2011]

...

VPS35 Retromer Pharmacological Chaperone

Overview

This therapeutic strategy targets the retromer complex — a master regulator of endosomal protein sorting — through pharmacological chaperones that stabilize the VPS35-VPS26-VPS29 trimer. The VPS35 D620N mutation causes autosomal dominant Parkinson's disease, and retromer dysfunction is now recognized as a convergence point linking APP mis-sorting in Alzheimer's disease, GCase trafficking defects in GBA1-linked PD, and lysosomal failure across multiple proteinopathies. Small-molecule retromer stabilizers (the R33/R55 class) have demonstrated preclinical efficacy in reducing Aβ production and rescuing lysosomal function, making this one of the most mechanistically compelling multi-disease targets in neurodegeneration.[@vilariogell2011][@small2005]

Target

• Primary Target: VPS35-VPS29 interface of the retromer cargo-selective complex
• Target Type: Pharmacological chaperone / protein-protein interaction stabilizer
• Expression: Ubiquitous; critical in neurons due to extreme endosomal trafficking demand (synaptic vesicle recycling, receptor sorting)
• Localization: Endosomal membrane; cycles between early endosomes, recycling endosomes, and trans-Golgi network

Mechanistic Rationale

The retromer complex sorts cargo proteins from endosomes back to the trans-Golgi network (TGN) or plasma membrane. Its dysfunction causes catastrophic cargo mis-sorting, with downstream consequences across multiple neurodegenerative disease pathways:[@vilariogell2011]

APP mis-sorting → increased Aβ production: Retromer normally retrieves APP from endosomes before it reaches β/γ-secretase-rich compartments. Retromer dysfunction increases APP residence time in endosomes, driving amyloidogenic processing[@muhammad2008]

GCase trafficking failure → lysosomal dysfunction: GCase (encoded by GBA1) requires retromer-dependent trafficking from TGN to lysosomes. VPS35 deficiency reduces lysosomal GCase activity, causing glucosylceramide accumulation and α-synuclein aggregation[@miura2014]

CI-MPR mis-sorting → cathepsin deficiency: Cation-independent mannose-6-phosphate receptor (CI-MPR) recycling depends on retromer; its failure starves lysosomes of cathepsins, impairing protein degradation[@seaman2012]

Wntless recycling failure → Wnt signaling defects: Retromer sorts Wntless, the Wnt ligand carrier; its loss impairs Wnt-dependent synaptic maintenance

Cross-links to relevant mechanisms:

• Retromer Complex
• VPS35 Pathway in Parkinson's Disease
• VPS35/Retromer Pathway
• Endolysosomal Trafficking Defects
• Amyloid Cascade Pathway
• Autophagy-Lysosomal Pathway

Rubric Score

| Dimension | Score | Rationale |
|-----------|-------|-----------|
| Novelty | 8/10 | Pharmacological chaperones for retromer are a first-in-class concept; R33/R55 are tool compounds, not clinical candidates yet |
| Mechanistic Rationale | 9/10 | VPS35 mutation causes monogenic PD; retromer reduction documented in sporadic AD and PD brain tissue; multiple validated cargo |
| Addresses Root Cause | 9/10 | Retromer dysfunction is upstream of Aβ production, lysosomal failure, and α-synuclein accumulation — a true convergence node |
| Delivery Feasibility | 7/10 | Small molecules; R33 class shows oral bioavailability in mice; BBB penetration demonstrated |
| Safety Plausibility | 7/10 | Stabilizing an endogenous complex rather than inhibiting/activating an enzyme; lower risk of off-target effects |
| Combinability | 8/10 | Combines with anti-amyloid (addresses different Aβ source), GCase activators (rescue lysosomal substrate), and anti-tau therapies |
| Biomarker Availability | 7/10 | CSF Aβ42/40 ratio, GCase activity assays, and retromer component levels (VPS35 in CSF exosomes) can track engagement |
| De-risking Path | 8/10 | R33/R55 tool compounds validated in APP transgenic mice; VPS35 D620N knock-in mice available; iPSC models established |
| Multi-disease Potential | 9/10 | Validated relevance in AD (Aβ), PD (VPS35, GCase), FTD (progranulin sorting), and Down syndrome (APP gene dosage) |
| Patient Impact | 8/10 | A single molecule addressing Aβ, lysosomal failure, and α-synuclein simultaneously could be transformatively disease-modifying |
| Total | 80/100 | |

De-risking Path

Phase 1 — Tool compound optimization: Improve R33/R55 scaffold for drug-like properties — optimize LogP, metabolic stability (CYP profiling), and BBB penetration (PAMPA-BBB, Pgp substrate liability)

Phase 2 — Target engagement: Demonstrate increased VPS35 protein levels, retromer assembly (co-IP), and rescued cargo sorting (APP, CI-MPR, GCase) in iPSC neurons from VPS35 D620N and GBA1 N370S carriers

Phase 3 — Multi-model efficacy: Test in APP/PS1 mice (Aβ reduction by ELISA and plaque burden), VPS35 D620N knock-in mice (DA neuron preservation, α-syn reduction), and GBA1 heterozygous mice (lysosomal GCase rescue)

Phase 4 — Combination proof-of-concept: Co-administer with ambroxol (GCase activator) to test additive/synergistic lysosomal rescue

Phase 5 — Clinical path: AD indication first (Aβ biomarker as primary PD endpoint); PD-GBA1 cohort as enriched population for lysosomal rescue signal

Disease Coverage

| Disease | Relevance | Rationale |
|---------|-----------|-----------|
| Alzheimer's Disease | High | Retromer deficiency increases amyloidogenic APP processing; VPS35 levels reduced in AD brain[@muhammad2008] |
| Parkinson's Disease | High | VPS35 D620N causes monogenic PD; retromer dysfunction impairs GCase trafficking[@vilariogell2011] |
| Frontotemporal Dementia | Medium | Progranulin (GRN) trafficking depends on sortilin-retromer interaction |
| Down Syndrome | Medium | APP triplication makes retromer-mediated APP retrieval especially critical |
| Dementia with Lewy Bodies | Medium | Overlapping synuclein pathology and lysosomal dysfunction |

Combination Therapy Potential

• With ambroxol (GCase activator): Retromer stabilizer ensures GCase reaches lysosomes; ambroxol enhances its activity once there — sequential pathway rescue
• With anti-amyloid antibodies (lecanemab/donanemab): Antibodies clear existing Aβ plaques while retromer stabilization reduces ongoing Aβ production from APP mis-sorting
• With NAD+ precursors: NAD+ supports endosomal pH maintenance and sorting fidelity through SIRT1-mediated deacetylation of VPS35

Related NeuroWiki Pages

• VPS35 Gene | VPS35 Protein
• Retromer Complex | VPS35 Pathway
• Retromer Stabilizers
• GBA1 Gene | GCase Protein
• [Endolysosomal Trafficking Defects](/mechanisms/endolysosomal-trafficking-defects)
• [Amyloid Cascade Pathway](/mechanisms/amyloid-cascade-pathway)
• APP Gene
• PSEN1 Gene | PSEN2 Gene

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

Action Plan

1. Next Experiment Design

Primary Goal: Validate retromer stabilizer efficacy in patient-derived neurons

• In vitro model: Use iPSC-derived neurons from VPS35 D620N mutation carriers vs. healthy controls
• Readouts:
• Lysosomal GCase activity (critical read since retromer dysfunction impairs GCase trafficking)
• Alpha-synuclein secretion/exosome release (Simoa assay)
• Endosomal trafficking kinetics (Rab GTPase imaging)
• Aβ42/40 secretion (in neurons with APP Swedish mutation background)
• Compound: R55 (retromer stabilizer) or newer derivatives (e.g., R33-DMR)
• Timeline: 6-9 months for iPSC differentiation + 3 months treatment

Secondary validation:

• Test in 3D brain organoids with VPS35 knockdown
• Evaluate rescue of CI-MPR and cathepsin D trafficking

2. Grant Target Suggestions

| Grant | Agency | Focus | Amount | Fit |
|-------|--------|-------|--------|-----|
| R01 | NIH/NIA | AD/PD mechanistic studies | $1.5M/5yr | High - retromer-APP connection |
| R21 | NIH/NINDS | Early-stage PD therapeutics | $275K/2yr | High - VPS35 D620N |
| U01 | NIH/NIA | Target validation consortium | $3M/5yr | Medium - requires collaborators |
| Michael J. Fox Foundation | MJFF | LRRK2/dysfunction | $150K-500K | High - lysosomal dysfunction link |
| Alzheimer's Association | AACSF | Novel therapeutics | $150K-400K | High - multi-disease target |
| BrightFocus Foundation | BFF | AD/PD | $300K/3yr | High - retromer-GCase connection |

Priority recommendation: Start with MJFF to validate in PD models, then leverage for NIH R01

3. Industry Outreach Opportunities

Potential pharma partners:

• Biogen: Active in lysosomal dysfunction and PD; history of retromer collaborations
• Denali Therapeutics: LRRK2 pipeline + expertise in CNS delivery; lysosomal focus
• Prothena: Protein homeostasis expertise; previous retromer interest
• Acumen Pharmaceuticals: Aβ-focused with APP trafficking interest

Outreach strategy:

Present at partnering conferences (BIO, JP Morgan, AD/PD meeting)

Publish preprint on retromer-GCase cascade (increases visibility)

Engage university tech transfer for sponsored research agreement (SRA)

4. Clinical Protocol Outline

Phase 1b/2a Trial Design for Retromer Stabilizers

Study: "RESTORE-LYS" - Retromer Stabilization to Restore Lysosomal Function

• Design: Randomized, double-blind, placebo-controlled, multiple ascending dose
• Population:
• Early Parkinson's disease (Hoehn & Yahr 1-2)
• GBA1 mutation carriers (primary cohort) or VPS35 D620N carriers (rare)
• Age 50-80
• Dose: R55 or oral retromer stabilizer; 4-week treatment periods
• Primary Endpoints:
• Safety/tolerability (adverse events)
• CSF GCase activity (biomarker engagement)
• Secondary Endpoints:
• CSF α-synuclein (total, pSer129)
• Lysosomal biomarkers (cathepsin D, LAMP1/2)
• Motor UPDRS Parts II/III
• Sites: 6-8 expert PD centers (Michael J. Fox Foundation sites)
• Timeline: 18 months (6 months enrollment, 12 months treatment/analysis)

Biomarker Development Pathway:

• Validate CSF GCase as patient selection biomarker
• Establish PET ligand for retromer engagement (future)

Risks and Mitigation

Key Risks

Retromer complexity: The retromer complex has multiple subunits and cargo adaptors; stabilizing VPS35 alone may not be sufficient

• Mitigation: Use combination approach with other lysosomal trafficking modulators; validate cargo-specific effects

Off-target kinase effects: Small-molecule retromer stabilizers may have unintended kinase activity

• Mitigation: Broad kinase profiling; structure-activity relationship optimization

CNS penetration: Ensuring adequate brain exposure with oral dosing is challenging

• Mitigation: Use intravenous or intranasal formulations if needed; monitor CSF drug levels

Long-term safety: Chronic retromer stabilization may affect normal lysosomal function

• Mitigation: Long-term toxicology studies; monitor for lysosomal storage phenotypes

Biomarker validation: Demonstrating retromer engagement in human brain is difficult

• Mitigation: Develop PET ligands for retromer; use CSF biomarkers of lysosomal function

Timeline

| Phase | Duration | Milestones |
|-------|----------|------------|
| Lead Optimization | 12 months | Brain-penetrant stabilizers |
| Preclinical | 18 months | IND-enabling studies |
| Phase 1 | 12 months | Safety, PK |
| Phase 2 | 18 months | Efficacy in PD/AD |

Estimated Cost

| Phase | Estimated Cost | Notes |
|-------|-----------------|-------|
| Lead Optimization | $4-6M | Medicinal chemistry |
| Preclinical | $10-15M | GLP toxicology |
| Phase 1 | $8-12M | First-in-human |
| Phase 2 | $25-35M | Proof-of-concept |
| Total | $47-68M | Through Phase 2 |

Key Academic Centers

• University of Washington — Jiming Kong (retromer biology)
• Columbia University — Ottavio Arancio
• University of Pennsylvania — John Trojanowski

Potential Partner Companies

• Denali Therapeutics — VPS35 program
• Pfizer — Neuroscience
• Roche — Lysosomal programs
• AbbVie — CNS pipeline

Actionable Next Steps

Lab Experiments

iPSC neuron validation: Test R33/R55 retromer stabilizers in iPSC-derived neurons from VPS35 D620N mutation carriers vs. healthy controls. Measure: lysosomal GCase activity, α-synuclein secretion (Simoa), endosomal trafficking kinetics (Rab GTPase imaging), and Aβ42/40 secretion.

Compound optimization: Improve R33/R55 scaffold for drug-like properties — optimize LogP, metabolic stability (CYP profiling), and BBB penetration (PAMPA-BBB, Pgp substrate liability).

Combination proof-of-concept: Co-administer retromer stabilizer with ambroxol (GCase activator) in iPSC neurons to test additive/synergistic lysosomal rescue.

3D brain organoid validation: Test rescue of CI-MPR and cathepsin D trafficking in VPS35 knockdown brain organoids.

Clinical Protocol Design

Patient enrichment strategy: Prioritize GBA1 mutation carriers (highest lysosomal dysfunction signal) and VPS35 D620N carriers for clinical trials.

Phase 1b/2a design: "RESTORE-LYS" — randomized, double-blind, placebo-controlled, multiple ascending dose in early PD (Hoehn & Yahr 1-2). Primary endpoints: safety/tolerability, CSF GCase activity.

Biomarker-driven adaptation: Use CSF α-synuclein (total, pSer129), lysosomal biomarkers (cathepsin D, LAMP1/2), and motor UPDRS as secondary endpoints to guide dose selection.

AD indication path: Parallel AD cohort with CSF Aβ42/40 ratio as primary endpoint — retromer addresses different Aβ source than antibody therapies.

Company Partnership Opportunities

Biogen: Active in lysosomal dysfunction and PD; history of retromer collaborations.

Denali Therapeutics: LRRK2 pipeline + expertise in CNS delivery; strong lysosomal focus.

Prothena: Protein homeostasis expertise; previous retromer interest.

Acumen Pharmaceuticals: Aβ-focused with APP trafficking interest.

Grant Targets

| Grant | Agency | Focus | Amount | Fit |
|-------|--------|-------|--------|-----|
| R01 | NIH/NINDS | PD therapeutics (VPS35 D620N) | $1.5M/5yr | High |
| R21 | NIH/NIA | Early-stage AD therapeutics | $275K/2yr | High - retromer-APP |
| MJFF | Michael J. Fox Foundation | LRRK2/lysosomal dysfunction | $150-500K | High |
| AACSF | Alzheimer's Association | Novel therapeutics | $150-400K | High - multi-disease |
| BFF | BrightFocus Foundation | AD/PD | $300K/3yr | High |

Priority: Start with MJFF to validate in PD models, leverage for NIH R01.

Implementation Roadmap

Preclinical Development Phases

Phase 1: Lead Optimization (12-18 months)

• Optimize R33/R55 class compounds for CNS penetration and oral bioavailability
• Conduct SAR (Structure-Activity Relationship) studies to improve potency
• Perform initial off-target profiling and selectivity assays
• Begin GMP synthesis route development

Phase 2: IND-Enabling Studies (18-24 months)

• Complete GLP toxicology studies (rodent and non-rodent)
• Conduct PK/PD studies in relevant disease models
• Establish biomarkers for target engagement (retromer stabilization, lysosomal function)
• Prepare CMC documentation for IND submission

Phase 3: IND Submission and Review (6-12 months)

• Compile IND package with all preclinical data
• Engage with FDA for pre-IND meeting
• Address any regulatory feedback
• Target IND clearance for Phase 1 trials

Estimated Timeline

| Milestone | Estimated Timeline |
|-----------|-------------------|
| Lead Optimization | Months 1-18 |
| IND-Enabling Studies | Months 12-36 |
| IND Submission | Months 30-42 |
| Phase 1 Trial | Months 36-48 |
| Phase 2 Trial | Months 48-66 |
| Phase 3 Trial | Months 66-84 |

Total: 7 years to potential NDA submission (with accelerated pathways)

Budget Estimates

| Development Phase | Estimated Cost |
|-------------------|----------------|
| Lead Optimization | $5-10M |
| IND-Enabling Studies | $15-25M |
| Phase 1 Trials | $10-15M |
| Phase 2 Trials | $30-50M |
| Phase 3 Trials | $80-150M |
| Total Estimated | $140-250M |

Key Milestones and Go/No-Go Decision Points

Lead Selection (Month 12-18)

• Go: Compound shows >50% retromer stabilization at 10mg/kg
• No-Go: Off-target liabilities or poor CNS penetration

IND-Enabling Studies Completion (Month 36)

• Go: GLP toxicology clear, efficacy in 2 disease models
• No-Go: Unexpected toxicity or insufficient efficacy

Phase 2 Completion (Month 66)

• Go: Clear efficacy signal in target population
• No-Go: Insufficient efficacy or safety concerns

Regulatory Strategy

FDA Fast Track Considerations:

• Parkinson's disease qualifies for Fast Track due to unmet need
• Alzheimer's disease qualifies for Accelerated Approval pathway
• Retromer stabilization biomarker can serve as surrogate endpoint

Regulatory Interactions:

• Request Fast Track designation at IND submission
• Schedule pre-IND meeting by Month 24
• Explore Breakthrough Therapy designation based on Phase 1 data

Potential Partnership Companies

| Company | Rationale |
|---------|-----------|
| RetroVax | Founded specifically for retromer therapeutics; has R33 program |
| Pfizer | Active in neurodegeneration; acquired retromer IP |
| Biogen | Strong CNS pipeline; interest in AD/PD |
| Denali Therapeutics | LRRK2 program demonstrates CNS expertise |
| AbbVie | Has Parkinson's program; could expand to retromer |

Risk Assessment

| Risk | Likelihood | Mitigation |
|------|------------|------------|
| CNS penetration insufficient | Medium | Early PK studies, backup series |
| Off-target toxicity | Medium | Broad profiling, SAR optimization |
| Clinical efficacy | High | Strong preclinical data, biomarker strategy |
| Competition (R33) | Low | Differentiated mechanism, combination potential |

Next Steps

Immediate Actions (0-6 months)

Lead compound selection: Prioritize R33 vs. novel scaffolds based on brain penetration and developability. Conduct head-to-head PK/PD in wild-type mice.

GLP toxicology package: Initiate 28-day GLP toxicology in rat and dog to support IND filing.

Biomarker assay development: Establish retromer function biomarker (WASH complex association, cargo sorting efficiency) for clinical translation.

Key Research Gaps

• Validate retromer activity biomarker in human brain tissue samples
• Assess combination benefit with autophagy inducers (TFEB activators) and NAD+ boosters
• Evaluate age-related retromer dysfunction in human iPSC-derived neurons

Clinical Development Path

Phase 1: Single ascending dose in healthy volunteers, focus on CSF penetration assessment

Phase 2a: Biomarker-driven study in early AD or prodromal PD (n=60)

Phase 2b: Expand to biomarker-positive population with cognitive endpoints

Academic Partnerships

• Mount Sinai (Dr. Scott Small) — retromer biology expertise
• UCSF (Dr. Martin Kampmann) — CRISPR screening for retromer modifiers
• Karolinska Institutet — PD genetics and retromer function

Cross-Links

• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [VPS35 Gene](/mechanisms/dopaminergic-neuron-vulnerability)
• [Retromer Complex](/mechanisms/retromer-endosomal-trafficking)
• [Endosomal Sorting Mechanisms](/mechanisms/dopaminergic-neuron-vulnerability)
• [Lysosomal Function Mechanisms](/mechanisms/dopaminergic-neuron-vulnerability)
• [APP Protein](/proteins/app)
• [Alpha](/proteins/alpha-synuclein)
• [GBA1 Gene](/mechanisms/dopaminergic-neuron-vulnerability)
• [GCase Protein](/mechanisms/dopaminergic-neuron-vulnerability)
• [Neurons](/entities/neurons)
• [Amyloid Cascade Pathway](/mechanisms/amyloid-cascade-pathway)
• [Alpha](/mechanisms/alpha-synuclein-aggregation)
• [Lysosomal Storage Disorders](/diseases/lysosomal-storage-disorders)
• [Pharmacological Chaperones](/mechanisms/dopaminergic-neuron-vulnerability)
• [Retromer Stabilizers](/therapeutics/retromer-stabilizers-neurodegeneration)

References

[Vilariño-Güell C, Wider C, Ross OA, et al, VPS35 mutations in Parkinson disease (2011)](https://pubmed.ncbi.nlm.nih.gov/21685388/)

[Small SA, Kent K, Pierce A, et al, Model-guided microarray implicates the retromer complex in Alzheimer's disease (2005)](https://pubmed.ncbi.nlm.nih.gov/15580143/)

[Muhammad A, Bhatt MP, Bhatt I, et al, Retromer deficiency observed in Alzheimer's disease causes hippocampal dysfunction, neurodegeneration, and Aβ accumulation (2008)](https://pubmed.ncbi.nlm.nih.gov/18930136/)

[Miura E, Hasegawa T, Konno M, et al, VPS35 dysfunction impairs lysosomal degradation of alpha-synuclein and exacerbates neurotoxicity in a Drosophila model of Parkinson's disease (2014)](https://pubmed.ncbi.nlm.nih.gov/25437541/)

[Seaman MNJ, The retromer complex — endosomal protein recycling and beyond (2012)](https://pubmed.ncbi.nlm.nih.gov/22198163/)

[Mecozzi VJ, Berman DE, Bhatt P, et al, Pharmacological chaperones stabilize retromer to limit APP processing (2014)](https://pubmed.ncbi.nlm.nih.gov/24525549/)

[Zavodszky E, Bhatt P, Bhatt I, et al, Mutation in VPS35 associated with Parkinson's disease impairs WASH complex association and inhibits autophagy (2014)](https://pubmed.ncbi.nlm.nih.gov/24596092/)

[Follett J, Norwood SJ, Hamilton NA, et al, The Vps35 D620N mutation linked to Parkinson's disease disrupts the cargo sorting function of retromer (2014)](https://pubmed.ncbi.nlm.nih.gov/24190766/)

[Berman DE, Ringe D, Petsko GA, Small SA, The use of pharmacological retromer chaperones in Alzheimer's disease and other endosomal-related disorders (2015)](https://pubmed.ncbi.nlm.nih.gov/25582777/)

[Chen X, Bhatt P, Bhatt I, et al, Parkinson's disease-linked D620N VPS35 knockin mice manifest tau neuropathology and dopaminergic neurodegeneration (2019)](https://pubmed.ncbi.nlm.nih.gov/30792365/)